Wellspan York Hospital, Department of Emergency Medicine, 1001 S George Street, York, PA 17403, United States of America.
Wellspan York Hospital, Department of Emergency Medicine, 1001 S George Street, York, PA 17403, United States of America.
Am J Emerg Med. 2023 Jul;69:173-179. doi: 10.1016/j.ajem.2023.04.044. Epub 2023 May 1.
The HEART score for risk stratifying chest pain patients in the emergency department (ED) has been widely adopted in clinical practice, but is often employed with nonconformant serial troponin measurements.
The primary objective of this study was to examine the utility of obtaining a second conventional 3-h troponin I (TnI) level in ED patients presenting with potential acute coronary syndrome (ACS), stratified by HEART score and duration of symptoms.
This was a retrospective cohort study of consecutive adult ED patients with a complete HEART score. We assessed the utility of repeat TnI measurement by examining the positivity rate of ΔTnI = [Second TnI] - [Initial TnI] stratified by HEART score and time elapsed since onset or resolution of symptoms. Major adverse cardiac events (MACE) within 6 weeks of index visit were assessed.
A total of 944 patients were included with 433 (45.9%) assigned a low risk HEART score 0-3. Of the 268 (61.9%) low risk HEART score patients receiving a second TnI, only 3 (1.1%, [0.2-3.2%]) resulted in a positive ΔTnI, one of which occurred in the setting of an elevated initial TnI. Overall, patients presenting within 3 h of symptoms were more likely to experience positive ΔTnI, index MACE and MACE at 6 weeks compared to patients presenting ≥3 h since symptoms onset/resolution and patients with unknown timing of symptoms (15.9% vs 11.0% vs 10.3%, p < 0.001; 10.0% vs 5.3% vs 4.6%, p = 0.021; 12.7% vs 6.6% vs 6.4%, p = 0.047).
Our data suggest serial measurement of conventional troponin provides limited added benefit in low risk HEART score patients, regardless of duration and timing of symptoms. Conversely, serial troponin measurement may confer utility in moderate/high risk HEART score patients, particularly those presenting within 3 h of symptoms.
用于风险分层急诊科胸痛患者的 HEART 评分已在临床实践中广泛应用,但通常与不符合规范的连续肌钙蛋白测量一起使用。
本研究的主要目的是研究在根据 HEART 评分和症状持续时间分层的情况下,对急诊科出现潜在急性冠状动脉综合征(ACS)的患者进行第二次常规 3 小时肌钙蛋白 I(TnI)检测的效果。
这是一项连续纳入具有完整 HEART 评分的成年急诊科患者的回顾性队列研究。我们通过检查 ΔTnI 的阳性率来评估重复 TnI 测量的效果,ΔTnI=[第二次 TnI]-[初始 TnI],并根据 HEART 评分和症状开始或缓解后的时间进行分层。评估索引就诊后 6 周内的主要不良心脏事件(MACE)。
共纳入 944 例患者,其中 433 例(45.9%)患者的 HEART 评分低危 0-3 分。在 268 例(61.9%)低危 HEART 评分患者中接受第二次 TnI 检测的患者中,只有 3 例(1.1%,[0.2-3.2%])的检测结果为阳性ΔTnI,其中 1 例发生在初始 TnI 升高的情况下。总体而言,与症状出现后 3 小时内就诊的患者相比,症状出现后 3 小时就诊的患者更有可能出现阳性ΔTnI、指数 MACE 和 6 周时的 MACE(15.9%比 11.0%比 10.3%,p<0.001;10.0%比 5.3%比 4.6%,p=0.021;12.7%比 6.6%比 6.4%,p=0.047)。
我们的数据表明,连续测量常规肌钙蛋白在低危 HEART 评分患者中提供的附加获益有限,而与症状的持续时间和时间无关。相反,连续肌钙蛋白测量可能对中/高危 HEART 评分患者有用,特别是在症状出现后 3 小时内就诊的患者。